These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 26993495

  • 1. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.
    Leung M, Leung DY, Wong VW.
    Diab Vasc Dis Res; 2016 May; 13(3):236-43. PubMed ID: 26993495
    [Abstract] [Full Text] [Related]

  • 2. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N.
    Cardiovasc Diabetol; 2017 Jan 21; 16(1):13. PubMed ID: 28109295
    [Abstract] [Full Text] [Related]

  • 3. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.
    Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M, Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2017 May 11; 16(1):63. PubMed ID: 28490337
    [Abstract] [Full Text] [Related]

  • 4. Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
    Giorda CB, Cioffi G, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP, DYDA 2 Investigators.
    Cardiovasc Drugs Ther; 2019 Oct 11; 33(5):547-555. PubMed ID: 31418140
    [Abstract] [Full Text] [Related]

  • 5. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study.
    Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K, PROLOGUE Study Investigators.
    Cardiovasc Diabetol; 2016 Sep 13; 15(1):134. PubMed ID: 27624168
    [Abstract] [Full Text] [Related]

  • 6. Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study.
    Ida S, Murata K, Betou K, Kobayashi C, Ishihara Y, Imataka K, Uchida A, Monguchi K, Kaneko R, Fujiwara R, Takahashi H.
    Cardiovasc Diabetol; 2016 Nov 04; 15(1):153. PubMed ID: 27809903
    [Abstract] [Full Text] [Related]

  • 7. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.
    Hashikata T, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, Kitasato L, Hashimoto T, Kameda R, Maekawa E, Shimohama T, Tojo T, Ako J.
    Heart Vessels; 2016 Aug 04; 31(8):1303-10. PubMed ID: 26266630
    [Abstract] [Full Text] [Related]

  • 8. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
    McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, Dutka DP.
    Circ Cardiovasc Imaging; 2014 Mar 04; 7(2):274-81. PubMed ID: 24503784
    [Abstract] [Full Text] [Related]

  • 9. Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design.
    Imazu M, Nakano A, Ito S, Hamasaki T, Kitakaze M, TOPLEVEL investigators and study coordinators.
    Cardiovasc Drugs Ther; 2019 Jun 04; 33(3):363-370. PubMed ID: 30850916
    [Abstract] [Full Text] [Related]

  • 10. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
    Tripolt NJ, Aberer F, Riedl R, Url J, Dimsity G, Meinitzer A, Stojakovic T, Aziz F, Hödl R, Brachtl G, Strunk D, Brodmann M, Hafner F, Sourij H.
    Cardiovasc Diabetol; 2018 May 17; 17(1):71. PubMed ID: 29773079
    [Abstract] [Full Text] [Related]

  • 11. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
    Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K.
    J Am Heart Assoc; 2013 Jan 28; 2(1):e003277. PubMed ID: 23525426
    [Abstract] [Full Text] [Related]

  • 12. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Diamant M, Serné EH, van Raalte DH.
    Arterioscler Thromb Vasc Biol; 2016 Oct 28; 36(10):2125-32. PubMed ID: 27562916
    [Abstract] [Full Text] [Related]

  • 13. Effects of sitagliptin on exercise capacity and hemodynamics in patients with type 2 diabetes mellitus and coronary artery disease.
    Fujimoto N, Moriwaki K, Takeuchi T, Sawai T, Sato Y, Kumagai N, Masuda J, Nakamori S, Ito M, Dohi K.
    Heart Vessels; 2020 May 28; 35(5):605-613. PubMed ID: 31641887
    [Abstract] [Full Text] [Related]

  • 14. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC, Chang KC, Lin SJ, Chien RN, Hung MJ, Chan YY, Kao Yang YH, Lai EC.
    Cardiovasc Diabetol; 2020 Feb 12; 19(1):17. PubMed ID: 32050968
    [Abstract] [Full Text] [Related]

  • 15. Impact of Improved Glycemic Control on Cardiac Function in Type 2 Diabetes Mellitus.
    Leung M, Wong VW, Hudson M, Leung DY.
    Circ Cardiovasc Imaging; 2016 Mar 12; 9(3):e003643. PubMed ID: 26962125
    [Abstract] [Full Text] [Related]

  • 16. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis.
    Zhang DP, Xu L, Wang LF, Wang HJ, Jiang F.
    Cardiovasc Diabetol; 2020 Jan 22; 19(1):10. PubMed ID: 31969144
    [Abstract] [Full Text] [Related]

  • 17. Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
    Tahara N, Yamagishi SI, Bekki M, Kodama N, Nakamura T, Sugiyama Y, Oshige T, Kumashiro Y, Honda A, Tahara A, Igata S, Fukumoto Y.
    Curr Vasc Pharmacol; 2016 Jan 22; 14(6):552-562. PubMed ID: 27357182
    [Abstract] [Full Text] [Related]

  • 18. Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
    Oe H, Nakamura K, Kihara H, Shimada K, Fukuda S, Takagi T, Miyoshi T, Hirata K, Yoshikawa J, Ito H, FESC, for Effect of a DPP-4 inhibitor on left ventricular diastolic dysfunction in patients with type 2 diabetes and diabetic cardiomyopathy (3D) study investigators.
    Cardiovasc Diabetol; 2015 Jun 19; 14():83. PubMed ID: 26084668
    [Abstract] [Full Text] [Related]

  • 19. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
    Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H.
    Circ J; 2013 Jun 19; 77(5):1337-44. PubMed ID: 23386232
    [Abstract] [Full Text] [Related]

  • 20. Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients.
    Dell'Oro R, Maloberti A, Nicoli F, Villa P, Gamba P, Bombelli M, Mancia G, Grassi G.
    High Blood Press Cardiovasc Prev; 2017 Dec 19; 24(4):393-400. PubMed ID: 28608024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.